Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

Th Bessede; P. Beuzeboc; F. Bladou; K. Fizazi; P. Mongiat-Artus; A. Villers

doi:10.1016/S1166-7087(11)70015-X

Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

Th Bessede, P. Beuzeboc, F. Bladou, K. Fizazi, P. Mongiat-Artus, A. Villers

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.

Titre traduit de la contribution	Strategies in castration-resistant prostate cancer
langue originale	Français
Pages (de - à)	S68-S71
journal	Progres en Urologie
Volume	21
Numéro de publication	SUPPL. 2
Les DOIs	https://doi.org/10.1016/S1166-7087(11)70015-X
état	Publié - 1 mars 2011

mots-clés

Abiraterone
Androgen receptor
Castration-resistant
Endothelin
Estrogens

Accès au document

10.1016/S1166-7087(11)70015-X

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{069cb6eca98c430e96fe2500d697aac4,

title = "Strat{\'e}gies th{\'e}rapeutiques du cancer de la prostate, r{\'e}sistant {\`a} la castration",

abstract = "according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.",

keywords = "Abiraterone, Androgen receptor, Castration-resistant, Endothelin, Estrogens",

author = "Th Bessede and P. Beuzeboc and F. Bladou and K. Fizazi and P. Mongiat-Artus and A. Villers",

year = "2011",

month = mar,

day = "1",

doi = "10.1016/S1166-7087(11)70015-X",

language = "Fran{\c c}ais",

volume = "21",

pages = "S68--S71",

journal = "Progres en Urologie",

issn = "1166-7087",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

AU - Bessede, Th

AU - Beuzeboc, P.

AU - Bladou, F.

AU - Fizazi, K.

AU - Mongiat-Artus, P.

AU - Villers, A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.

AB - according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.

KW - Abiraterone

KW - Androgen receptor

KW - Castration-resistant

KW - Endothelin

KW - Estrogens

UR - http://www.scopus.com/inward/record.url?scp=79952605196&partnerID=8YFLogxK

U2 - 10.1016/S1166-7087(11)70015-X

DO - 10.1016/S1166-7087(11)70015-X

M3 - Article

C2 - 21397833

AN - SCOPUS:79952605196

SN - 1166-7087

VL - 21

SP - S68-S71

JO - Progres en Urologie

JF - Progres en Urologie

IS - SUPPL. 2

ER -